Therefore, in this retrospective study, we aimed to characterize serious hepatotoxicity due to osimertinib after nivolumab treatment in patients with previously treated NSCLC harboring the EGFR mutation. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.